Search Results
-
Post
Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®
...scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment. Please see http://www.optune.com/safety to see the Optune Instructions For Use (IFU) for complete information regarding...
-
Post
ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
...that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable,...
-
Post
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
...Optune, including battery (Photo: Business Wire) Download Full Size Small Preview Thumbnail ???pagination.previous??? ???pagination.next??? Second generation Optune, including battery (Photo: Business Wire) Full Size Small Preview Thumbnail First patient use...
-
Post
Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System
...indications. About Optune Lua Optune Lua is a noninvasive, antimitotic cancer treatment for MPM. Optune Lua delivers Tumor Treating Fields to the region of the tumor. Tumor Treating Fields is...
-
Post
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
...proud of this accomplishment and will continue working diligently to expand access to GBM patients who may benefit.” About Optune Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune...
-
Post
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
...can be prescribed, please visit OptuneLuaCenters.com. About Optune Lua Optune Lua is a noninvasive, antimitotic cancer treatment for MPM. Optune Lua delivers Tumor Treating Fields to the region of the...
-
Post
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
...may drive increased average usage and improve patient outcomes.” About Optune Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to the region of the...
-
Post
Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma
...alone: 43 percent versus 29 percent. In addition, the trial showed Optune could be safely combined with temozolomide. There was no significant increase in systemic toxicities from Optune in combination...
-
Post
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Optune is now available as a treatment for newly diagnosed glioblastoma patients in France ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide...
-
Post
Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
...of Israel. “Access to our therapy continues to grow throughout the world, demonstrating health insurers’ increasing recognition of Optune. We are committed to bringing Optune to as many patients who...